Northwire Canada EditionThursday, October 15, 2026
Northwire
⌕
GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4% GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4%
Production / Operations

NuGen Medical Devices Inc. Provides Update on Health Canada License

NGMD · Price

Executive Summary

  • NuGen Medical Devices Inc. has temporarily halted sales of its devices in Canada because its Health Canada licence expired.
  • The lapse is due to a delayed certificate renewal and does not reflect any regulatory enforcement action or product safety issue.
  • A new licence application has been submitted; the company expects renewal soon and plans to resume Canadian sales once approved.

Key Details

  • The Health Canada licence for NuGen’s devices became expired because the required renewal certificate was not filed on time.
  • This expiration triggers a temporary halt of device sales in Canada; no devices are being sold in the Canadian market until the licence is reinstated.
  • The company emphasizes that the situation does not constitute a suspension, cancellation, or safety risk related to regulatory compliance or enforcement actions.
  • NuGen has already filed an application for a new licence and is maintaining active communication with Health Canada throughout the review process.
  • The company is confident that the licence will be renewed shortly, after which Canadian sales are expected to resume.
  • Operations and sales in all other regions worldwide remain unaffected by this licensing issue.
  • NuGen commits to providing further updates as more information becomes available.

Notable Quotes

  • “NuGen is confident the licence will be renewed soon, and sales will resume once the new licence becomes available.” – Liang Lin, Chief Executive Officer.
Read the original news release →

More from Nugen Medical Devices Inc.